What Standard Protocols Should Practitioners Follow To Adjust Laser Dosage In Subsequent Phototherapy Sessions For Psoriasis? Evidence-Based Guidance For 15-25% Dose Adjustments Based On Tissue Response.

For subsequent psoriasis phototherapy sessions, adjust fluence according to the patient’s delayed tissue response and tolerance, usually assessed about 24 hours after treatment and within a 12–72-hour window. If there is no erythema or plaque improvement, increase fluence by approximately 15%–25%. Maintain the dose when mild erythema, plaque thinning, or reduced scaling occurs; reduce it by about 25% when plaques have improved substantially or when significant erythema, tenderness, or pain develops.

The correct adjustment is guided by the response of the treated plaque, not by a fixed escalation schedule. Dose increases should remain conservative, while blistering, severe pain, or marked erythema requires dose reduction, treatment review, and avoidance of further exposure to injured skin.

How to Judge the Response Before the Next Session

Assess the delayed reaction

Evaluate the treated areas after treatment, typically at 24 hours, while considering the full clinical response through approximately 72 hours. Document erythema, tenderness, blistering, plaque thickness, scaling, and overall improvement.

A response that is mild and tolerable generally indicates that the current fluence is appropriate. A delayed or severe reaction may require more cautious adjustment than the immediate appearance suggests.

Increase the dose only when the response is inadequate

If there is no erythema and no meaningful plaque improvement, increase fluence by approximately 15%–25% for the next session.

Protocols that distinguish degrees of inadequate response may use a 25% increase when there is no effect and a smaller 15% increase when the effect is minimal. The exact increment should remain consistent with the device protocol, treated site, skin type, and clinician judgment.

Maintain the dose when treatment is working

Maintain the same fluence when the patient develops mild erythema, plaque thinning, or reduced scaling without significant discomfort.

This response indicates that the tissue is reacting therapeutically. Increasing the dose despite an adequate response may add irritation without improving efficacy.

Reduce the dose after substantial improvement

When there is significant plaque improvement or near-clearance, reduce fluence by approximately 25% to limit unnecessary inflammation and the risk of post-inflammatory hyperpigmentation.

Dose reduction is particularly relevant in patients with darker skin types, recently tanned skin, or sites that are more prone to pigmentary change.

Responding to Adverse Tissue Reactions

Severe erythema, tenderness, or pain

Reduce the next fluence by approximately 15%–25% when marked erythema, significant tenderness, or pain develops.

The patient should be reassessed before further treatment. Persistent or worsening inflammation may require holding treatment rather than simply applying the reduced dose.

Blistering requires treatment interruption

Blistering is not an expected endpoint for routine psoriasis phototherapy dosing. The affected area should not be treated directly again until it is fully healed.

The episode should prompt review of the delivered fluence, treatment geometry, skin condition, and whether overlapping exposure occurred.

Avoid overlapping exposures

Practitioners should avoid treating the same area twice during one session or overlapping treatment fields. Repeated exposure can create a localized excess of thermal or photobiologic energy and increase the risk of severe erythema, pain, or blistering.

Accurate lesion marking and consistent treatment positioning are important safeguards.

Adjusting Treatment After Missed Sessions

One week missed

For psoriasis protocols, resume at the last administered dose, provided the skin has healed and there is no new contraindication or abnormal reaction.

The patient should still be examined before treatment rather than automatically receiving the previous fluence.

Two weeks missed

After a two-week interruption, decrease fluence by approximately 25% from the last administered dose before resuming.

This reduction accounts for the possibility that tolerance has changed during the treatment gap. Subsequent adjustments should again be based on the observed tissue response.

Three weeks missed

After a three-week interruption, reassess the patient and restart according to the initial dosing guidelines.

The reassessment should consider plaque induration, skin type, tanning, treated anatomical sites, current medications, and any interval adverse reactions.

Establishing a Safe Starting Point

Use MED testing when appropriate

Initial dosing may be based on Minimal Erythema Dose testing or on a direct assessment of plaque characteristics and Fitzpatrick skin type, depending on the equipment and clinical protocol.

MED-based dosing can account for plaque thickness, anatomical location, and tanning. Thick, tanned plaques on areas such as elbows or knees may require higher starting fluences than thin, non-tanned plaques.

Consider plaque severity and skin type

Protocols may use starting ranges of approximately 300–400 mJ/cm² for mild induration, 500–600 mJ/cm² for moderate induration, and 700–900 mJ/cm² for severe induration.

These figures are protocol- and device-dependent. They should not replace the manufacturer’s instructions, local clinical standards, or individualized assessment.

Keep subsequent treatments consistent

Use the same measurement units, treatment area definitions, and device settings at every visit. Consistent documentation makes it possible to distinguish an ineffective dose from inconsistent delivery.

What Practitioners Should Record

Document the delivered exposure

Each session record should include:

Fluence and other relevant device settings
Anatomical areas treated
Treated body surface area
Total or cumulative energy delivered
Treatment frequency and any missed sessions
Erythema, tenderness, blistering, and plaque response

These records are essential when determining whether a dose change reflects the patient’s biology, a change in treatment area, or an interruption in therapy.

Audit inadequate response

If there is no meaningful plaque reduction after approximately 20 sessions given two to three times weekly, review dosing adequacy, treatment consistency, diagnosis, adherence, and other clinical factors.

If the dose is already appropriate and treatment remains ineffective, continued escalation is not automatically justified. Treatment cessation or a different therapeutic strategy should be considered by the treating clinician.

Understanding the Trade-offs

Escalation improves exposure but raises injury risk

Increasing fluence can help when plaques show no therapeutic response, but each escalation also increases the risk of excessive erythema, pain, blistering, and pigmentary change.

The safest escalation is therefore incremental and response-based rather than automatic.

Reducing too quickly may limit efficacy

A dose reduction is appropriate after substantial improvement or significant toxicity. Reducing the dose solely because mild, tolerable erythema is present may unnecessarily weaken treatment.

The objective is a controlled therapeutic response, not the complete absence of erythema.

Fixed schedules cannot replace clinical assessment

The percentages and missed-session rules provide a framework, but they are not substitutes for examination. Skin type, tanning, plaque thickness, anatomical location, device characteristics, and prior reactions can materially change the appropriate dose.

Maintenance should be planned after clearance

For patients who achieve substantial plaque clearance, immediate cessation may not be the only option. Some clinic protocols use a structured taper, such as weekly treatments for four weeks, every two weeks for four weeks, and one final treatment four weeks later.

Any maintenance plan should be individualized and accompanied by continued monitoring and sun-protection advice.

Making the Right Choice for Your Goal

Choose the adjustment that matches the observed response and the treatment context.

If your primary focus is inadequate plaque response: Increase fluence conservatively by approximately 15%–25% after confirming that the prior session produced no meaningful erythema or plaque improvement.
If your primary focus is maintaining a therapeutic response: Keep the dose unchanged when mild erythema, plaque thinning, or reduced scaling occurs without significant discomfort.
If your primary focus is minimizing adverse effects: Reduce fluence by approximately 15%–25% for severe erythema, tenderness, or pain, and stop treating blistered areas until fully healed.
If your primary focus is resuming treatment after an interruption: Resume the last dose after a one-week gap, reduce it by 25% after two weeks, and reassess from the initial protocol after three weeks.
If your primary focus is preventing treatment errors: Record fluence, treated area, total energy, and tissue response while preventing overlap or duplicate exposure within a session.

A disciplined response-based protocol keeps psoriasis phototherapy effective while limiting avoidable tissue injury and pigmentary complications.

Summary Table:

Response	Dose Adjustment
No erythema or improvement	Increase by 15%–25%
Mild erythema, plaque thinning	Maintain current dose
Significant improvement	Decrease by 25%
Severe erythema, tenderness	Decrease by 15%–25%
Blistering	Stop treatment until healed
Missed 1 week	Resume last dose
Missed 2 weeks	Decrease by 25%
Missed 3 weeks	Restart initial protocol

For professional-grade laser and light-based devices that enable precise, response-based psoriasis dosing, trust BELIS. Our advanced systems—including excimer and narrowband UVB—help you achieve optimal outcomes with safety. Contact us today to learn how we support clinics and premium salons with cutting-edge technology and expert guidance.